

CanREValue

Value-based decisions from Real World Evidence

Spring 2022 Newsletter

Issue 14 | Spring 2022

Study Objectives:

Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and beyond

Objective 2: (established & ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

Objective 3: (ongoing)

- ❖ Validate the developed framework through the completion of a multi-province RWE project

Objective 4: (ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

CANREVALUE PRESENTING AT #ARCC2022

The 11th Annual Canadian Centre for Applied Research in Cancer Control (ARCC) Conference is being held virtually from May 16th-17th, 2022. The ARCC Conference is Canada's only applied cancer control research conference, bringing together policy and decision makers, researchers, clinicians, trainees, and other stakeholders to share work in the areas of health economics, services, policy, and ethics as it relates to cancer control in Canada. Plenary sessions will discuss issues related to data access in Canada, and ongoing impacts of the COVID-19 pandemic. Information is updated regularly on the conference website at <https://cc-arcc.ca/arcc-conference-2022/>.

CanREValue will be presenting the following work at ARCC 2022:

1. What's in our way? The challenges and recommendations for the generation of real-world evidence for oncology drug funding decisions; (Caroline Muñoz)
2. Engaging Patients in the CanREValue Initiative: Processes and Lessons Learned; (Pam Takhar)

Register today at <https://events.eply.com/2022ARCC>.

Please email us at CanREValue@cc-arcc.ca if you have any questions or need additional information about the 2022 ARCC Conference.

CANREVALUE PATIENT ENGAGEMENT – ENGAGEMENT WORKING GROUP

In August and October 2021, the CanREValue Engagement Working Group held two patient consultations, in collaboration with five prominent patient advocates serving as the patient organizing committee, to capture patients’ perspectives on important policy and data access issues described in the [Policy](#) and [Data](#) Working Group Interim reports. Collaborating patient advocates included Louise Binder, Martine Elias, Valerie McDonald, Stéphanie Michaud, and Christina Sit. The CanREValue team has learned valuable lessons and received key feedback reflecting the patient voice from these consultations. Specifically, patient advocates discussed how RWE could impact access to new drugs, how the RWE framework could support conditional drug approvals, and the importance of exploring data elements that speak to the patient perspective. The consultations have given us the opportunity to reflect more generally on how patient engagement strengthens our working groups and the CanREValue framework as a whole, and how we can further engage patients and embed the patient perspective within the CanREValue Collaboration.

Contact CanREValue@cc-arcc.ca should you have any questions regarding the Patient Engagement sessions or the Engagement Working Group.

WORKING GROUP UPDATES AND NEXT STEPS:

Working Group	Updates & Next Steps
Planning and Drug Selection	<p>Updates:</p> <ul style="list-style-type: none"> • Third MCDA Soft Launch held on February 23rd, 2022. <p>Next Steps:</p> <ul style="list-style-type: none"> • Continue assessing the MCDA rating tool. Next soft launch will take place during Summer 2022 • Submit MCDA commentary article for publication (currently under final revision)
Data	<p>Updates:</p> <ul style="list-style-type: none"> • Manuscripts on the real-world effectiveness and cost-effectiveness from ON published (see Recent Publications) • Held 2 interprovincial meetings to discuss analytical issues in each province in December 2021 and April 2022 <p>Next Steps:</p> <ul style="list-style-type: none"> • Continue with real-world analysis in 9 provinces
Methods	<p>Next Steps:</p> <ul style="list-style-type: none"> • Consult and discuss appropriate methodology for next identified outcome measure • Continue support of Data WG on 9 province analysis
Reassessment and Uptake	<p>Updates:</p> <ul style="list-style-type: none"> • Exploring the opportunities to operationalize Step 4 through a demonstration project. <p>Next Steps:</p> <ul style="list-style-type: none"> • Continue working with WG members and relevant stakeholders to further operationalize Step 4 through a demonstration project.
Engagement	<p>Updates:</p> <ul style="list-style-type: none"> • Held a teleconference to explore strategies for future engagement opportunities with clinicians, patients/advocacy groups, and industry. WG members also discussed next steps and explored strategies to effectively adopt/implement the CanREValue Framework.

Next Steps:

- Submit manuscript of patient engagement experience (currently under final revision)

MEMBER SPOTLIGHT – JACLYN BECA, MANAGER, ARCC NETWORK

Q: What is your educational background and how did it lead to an interest in RWE?

My educational training is in health services research, health economics, and health technology assessment, with an undergraduate background in biology. Working in the Pharmacoeconomics Research Unit over the last twelve years, we have had a long history of integrating methods from these disciplines to estimate and assess the value of medicines in delivering expected outcomes. These analyses require both clinical understanding of disease processes and

methodological expertise to ensure comparisons are fair and

unbiased, which gives me an opportunity to apply all my academic training and skillsets. When applied to policy, these studies aim to advance knowledge and support better decision-making by addressing uncertainties from initial evidence, which is very meaningful to me.



Q: What aspect of the CanREValue project are you the most excited to work on?

I have long been interested in the intersection of high-quality methods and policy decision-making, so the areas that connect these two realms, from priority-setting approaches to developing policy tools to help enable action are the areas that excite me the most about this work. I am always keen to find innovative ways to meet the needs of the end users and translate evidence into meaningful insights.

Q: What has been the most interesting aspect of this project for you so far?

This project brings together such a diverse range of people in our group of stakeholders, who work in the same system for largely the same goals, and yet each brings their own rich experiences and expertise. Developing a deeper understanding of the ways in which we conceptualize value similarly and differently from our viewpoints across the spectrum of the health technology assessment and reimbursement landscape is an invaluable takeaway for me. It serves to remind me to be aware of the limitations of my own perspective and makes me very grateful to be part of such an extraordinary collaboration!

You can email me at jaclyn.beca@ontariohealth.ca.

Recent Publications/Presentations:**Manuscripts:**

Dai WF, de Oliveira C, Blommaert S, Pataky RE, Tran D, Aurangzeb Z, Kendell C, Folkins C, Somayaji C, Dowden J, Cheung W, Strumpf E, Beca JM, McClure C, Urquhart R, McDonald JT, Alvi R, Turner D, Peacock S, Denburg A, Mercer RE, Muñoz C, Parmar A, Tadrous M, Takhar P, Chan KKW, on behalf of the CanREValue Collaboration. [Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs \(CanREValue\) Collaboration's RWE Data Working Group](#). *Current Oncology*. 2022; 29(3):2046-2063. <https://doi.org/10.3390/curroncol29030165>

Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Chan KKW. [Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer](#). *JAMA Oncol*. 2022 Feb 24:e218049. doi: 10.1001/jamaoncol.2021.8049. Epub ahead of print. PMID: 35201264; PMCID: PMC8874900.

Dai WF, Beca JM, Nagamuthu C, Liu N, de Oliveira C, Earle CC, Trudeau M, Mercer RE, Chan KKW. [Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer](#). *JAMA Netw Open*. 2022 Feb 1;5(2):e2145460. doi: 10.1001/jamanetworkopen.2021.45460. PMID: 35226087; PMCID: PMC8886524.